Akari net loss widens to $4.81 million in Q2 FY26; operating loss rises to $4.6 million
Reuters2026/08/13 20:04- Akari Therapeutics posted a GAAP net loss of $4.81 million for the quarter ended June 30, 2026, widening from $1.9 million.
- Operating loss widened to $4.6 million from $3.12 million, while R&D spending rose to $2.08 million from $667,000.
- Cash totaled $7.7 million at June 30, 2026, with management expecting runway into December 2026.
- A $5.2 million May private placement closed; the White Lion $25 million equity line resale registration was declared effective July 7, 2026.
- AKTX-101 GMP manufacturing began with WuXi Biologics/XDC; first-in-human trials targeted for mid-2027, with a July Whitehawk collaboration announced.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
OPEC+ agrees to keep oil output policy unchanged for October
US military strikes Iranian oil tanker, triggering geopolitical risks as Brent crude nears $97 mark
Following the US military's attack on Iranian oil tankers and Iran's announcement of new restricted navigation zones outside the Strait of Hormuz, market concerns over prolonged disruptions in key energy transport routes have intensified, leading to a sharp rise in international oil prices.
Geopolitical tensions overshadowing production cuts: OPEC+ maintains quotas unchanged, paper adjustments fail to resolve physical supply dilemmas
OPEC+ major oil producers, led by Saudi Arabia and Russia, held a monthly video conference last Sunday and decided to keep the crude oil production quota for October unchanged, continuing the previous tone of stable production following a series of symbolic production increases.
IX Biopharma seeks SGX-ST trading halt lift for shares in Singapore
Crypto prices
More
